 DUBLIN, April 28, 2021 PRNewswire -- Alkermes plc Nasdaq: ALKS today announced the acceptance of two abstracts related to nemvaleukin alfa nemvaleukin, the companys novel, investigational engineered interleukin-2 IL-2 variant immunotherapy, at the 2021 American Society of Clinical Oncology ASCO Annual Meeting, taking place virtually June 4-8, 2021. New data from the phase 12 ARTISTRY-1 clinical trial evaluating the tolerability and efficacy of nemvaleukin administered intravenously as a monotherapy and in combination with pembrolizumab KEYTRUDA will be shared in a poster discussion session. 